SG11202105767YA - Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1 - Google Patents
Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1Info
- Publication number
- SG11202105767YA SG11202105767YA SG11202105767YA SG11202105767YA SG11202105767YA SG 11202105767Y A SG11202105767Y A SG 11202105767YA SG 11202105767Y A SG11202105767Y A SG 11202105767YA SG 11202105767Y A SG11202105767Y A SG 11202105767YA SG 11202105767Y A SG11202105767Y A SG 11202105767YA
- Authority
- SG
- Singapore
- Prior art keywords
- hapln1
- relieving
- symptoms
- preventing
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2019/002418 WO2020175721A1 (en) | 2019-02-28 | 2019-02-28 | Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105767YA true SG11202105767YA (en) | 2021-06-29 |
Family
ID=72238712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105767YA SG11202105767YA (en) | 2019-02-28 | 2019-02-28 | Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230158106A1 (en) |
| EP (1) | EP3888664A4 (en) |
| JP (1) | JP7302903B2 (en) |
| CN (1) | CN113490500A (en) |
| AU (1) | AU2019431082B2 (en) |
| BR (1) | BR112021013538A2 (en) |
| CA (1) | CA3122250C (en) |
| CO (1) | CO2021009034A2 (en) |
| IL (1) | IL283551A (en) |
| MX (1) | MX2021008327A (en) |
| PE (1) | PE20230436A1 (en) |
| SG (1) | SG11202105767YA (en) |
| WO (1) | WO2020175721A1 (en) |
| ZA (1) | ZA202103815B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011126833A2 (en) | 2010-03-29 | 2011-10-13 | Massachusetts Institute Of Technology | Anti-inflammatory factors |
| US20140178988A1 (en) * | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
| WO2014130411A1 (en) * | 2013-02-22 | 2014-08-28 | Emory University | Tgf-beta enhancing compositions for cartilage repair and methods related thereto |
| CA2923857A1 (en) | 2013-09-09 | 2015-03-12 | Figene, Llc | Gene therapy for the regeneration of chondrocytes or cartilage type cells |
| DK3242888T3 (en) * | 2015-01-07 | 2021-02-15 | Pfizer | SOLUBLE FGFR3 STEPS FOR THE TREATMENT OF SKELETON GROWTH DISORDERS |
| JP2019501943A (en) | 2016-01-14 | 2019-01-24 | スパイナルサイト， エルエルシー | Cell composite for regenerating chondrocytes or chondrocytes |
| CA3055168C (en) * | 2017-03-06 | 2022-09-06 | Haplnscience inc. | Composition for skin aging measurement, prevention, or alleviation using hapln1 |
| KR20190024727A (en) | 2017-08-29 | 2019-03-08 | 중앙대학교 산학협력단 | Composition for cartilage regeneration comprising HAPLN1 |
-
2019
- 2019-02-28 MX MX2021008327A patent/MX2021008327A/en unknown
- 2019-02-28 AU AU2019431082A patent/AU2019431082B2/en not_active Ceased
- 2019-02-28 CN CN201980093146.6A patent/CN113490500A/en active Pending
- 2019-02-28 PE PE2021001148A patent/PE20230436A1/en unknown
- 2019-02-28 US US17/297,707 patent/US20230158106A1/en not_active Abandoned
- 2019-02-28 EP EP19917174.5A patent/EP3888664A4/en active Pending
- 2019-02-28 CA CA3122250A patent/CA3122250C/en active Active
- 2019-02-28 JP JP2021549676A patent/JP7302903B2/en active Active
- 2019-02-28 SG SG11202105767YA patent/SG11202105767YA/en unknown
- 2019-02-28 BR BR112021013538-3A patent/BR112021013538A2/en not_active Application Discontinuation
- 2019-02-28 WO PCT/KR2019/002418 patent/WO2020175721A1/en active Application Filing
-
2021
- 2021-05-30 IL IL283551A patent/IL283551A/en unknown
- 2021-06-03 ZA ZA2021/03815A patent/ZA202103815B/en unknown
- 2021-07-09 CO CONC2021/0009034A patent/CO2021009034A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019431082B2 (en) | 2022-12-15 |
| CA3122250A1 (en) | 2020-09-03 |
| PE20230436A1 (en) | 2023-03-08 |
| CO2021009034A2 (en) | 2021-07-30 |
| EP3888664A1 (en) | 2021-10-06 |
| JP7302903B2 (en) | 2023-07-04 |
| CA3122250C (en) | 2023-12-12 |
| AU2019431082A1 (en) | 2021-07-01 |
| BR112021013538A2 (en) | 2021-09-14 |
| IL283551A (en) | 2021-07-29 |
| CN113490500A (en) | 2021-10-08 |
| EP3888664A4 (en) | 2021-12-15 |
| WO2020175721A1 (en) | 2020-09-03 |
| US20230158106A1 (en) | 2023-05-25 |
| MX2021008327A (en) | 2021-08-11 |
| ZA202103815B (en) | 2022-09-28 |
| JP2022522144A (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518390944B1 (en) | Tissue factor pathway inhibitor antibodies and uses thereof | |
| WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
| EP3266317A4 (en) | Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient | |
| SG11202107562VA (en) | Composition for preventing, alleviating or treating neurodegenerative diseases, comprising pediococcus inopinatus | |
| SG11202107310RA (en) | Defensin fragments for use in therapy or prophylaxis | |
| IL287831A (en) | Oxymetazoline compositions and methods for treating ocular disorders | |
| MX2019002149A (en) | Method for treating pruritus and/or itch. | |
| EP4190346A4 (en) | Composition for preventing or treating inflammatory diseases, and use thereof | |
| EP3708161A4 (en) | Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor | |
| HUE053924T2 (en) | Composition for treating diabetic disease | |
| EP3980047C0 (en) | Inflammatory disease treatment with complement inhibitors | |
| ZA202103815B (en) | Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1 | |
| EP3970793A4 (en) | Agent for preventing, ameliorating, or treating periodontal disease | |
| EP3927375A4 (en) | Compositions for disease treatment | |
| PL3810128T3 (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| EP4190916A4 (en) | Composition for diagnosing musculoskeletal diseases, composition for preventing or treating musculoskeletal diseases, and use thereof | |
| PL4021433T3 (en) | Treatment of menstrual cycle-induced symptoms | |
| IL291037A (en) | Composition for diagnosing or treating conditions associated with increased elf4e activity comprising elf4e inhibitor | |
| ZA202107513B (en) | Compounds and compositions comprising the same for treating hypertension or heart failure | |
| IL286625A (en) | Compositions and methods for treating ocular disease | |
| KR102324922B9 (en) | Pharmaceutical composition comprising osteocalcin for preventing or treating inflammatory diseases | |
| EP3971174C0 (en) | Hydrophilic metal-surface treatment agent | |
| PL3773641T3 (en) | Topical pharmaceutical compositions for treating skin conditions | |
| EA201890007A1 (en) | MULTIPEPTID COMPOSITION | |
| EP3326636A4 (en) | Amyloid beta fibril decomposing agent, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by amyloid beta fibril formation |